anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Immix Biopharma · pitchdeck

Immix Biopharma | Investor Presentation Deck | 49 slides

49 pages · 5 arc beats · 3 loops

Pitchdeck Download JSON
Unlock

Immix Biopharma | Investor Presentation Deck | 49 slides

Immix Biopharma · 2023-08
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 49 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Situation & Context 4 slides 100% 4/4 slides 100% 4/4 slides · 15 hits
— 0/4 slides
— 0/4 slides
25% 1/4 slides 100% 4/4 slides
— 0/4 slides
Problem & Complication 3 slides 100% 3/3 slides 100% 3/3 slides · 14 hits
— 0/3 slides
— 0/3 slides
66.7% 2/3 slides 100% 3/3 slides 33.3% 1/3 slides Evidence & Proof 14 slides 100% 14/14 slides 100% 14/14 slides · 68 hits
— 0/14 slides
50% 7/14 slides · 8 hits 57.1% 8/14 slides 100% 14/14 slides 100% 14/14 slides · 19 hits Impact & Next Steps 15 slides 100% 15/15 slides 100% 15/15 slides · 73 hits
— 0/15 slides
46.7% 7/15 slides 33.3% 5/15 slides 100% 15/15 slides 100% 15/15 slides Solution & Approach 13 slides 100% 13/13 slides 100% 13/13 slides · 69 hits
— 0/13 slides
38.5% 5/13 slides 23.1% 3/13 slides 100% 13/13 slides
— 0/13 slides

Slide inventory

49
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detailBeat · Situation & Context
02
other
Open slide detailBeat · Situation & Context
03
The slide uses a numbered list format to present key value propositions.summarize
Open slide detailBeat · Situation & Context
04
The slide highlights two distinct pipelines: N-GENIUS (cell therapy) and SMARxT (tissue-specific).summarize
Open slide detailBeat · Situation & Context
05
The slide uses a stylized area chart to represent market segments and their associated financial opportunities.size_opportunity
Open slide detailBeat · Problem & Complication
06
The table uses a standard pharmaceutical pipeline layout with clinical and preclinical segments.show_traction
Open slide detailBeat · Problem & Complication
07
The slide uses a hub-and-spoke diagram to illustrate the negative consequences of neurotoxicity.frame_problem
Open slide detailBeat · Problem & ComplicationLoop · Cost Of Inaction
08
Includes a cartoon liver character, likely representing the target organ or safety profile.present_solution
Open slide detailBeat · Evidence & ProofLoop · Cost Of Inaction
09
Includes extensive disclaimer text regarding cross-trial comparison limitations.compare_peers
Open slide detailBeat · Evidence & ProofLoop · Cost Of Inaction
10
Includes detailed source citations in the footer.compare_peers
Open slide detailBeat · Evidence & ProofLoop · Cost Of Inaction
11
Includes detailed source citations in the footer; uses a color-coded legend for different drug treatments.compare_peers
Open slide detailBeat · Evidence & ProofLoop · Cost Of Inaction
12
The slide uses a two-column layout to separate milestones by drug candidate.plan_implementation
Open slide detailBeat · Evidence & ProofLoop · Cost Of Inaction
13
present_solution
Open slide detailBeat · Evidence & ProofLoop · Cost Of Inaction
14
transition
Open slide detailBeat · Evidence & ProofLoop · Cost Of Inaction
15
The slide uses a table structure to contrast clinical outcomes across three key value pillars: response rates, tolerability, and outpatient feasibility.present_solution
Open slide detailBeat · Evidence & ProofLoop · Cost Of Inaction
16
Includes comparative data points for transduction efficiency and experimental data for tonic signaling and anti-exhaustion.present_solution
Open slide detailBeat · Evidence & ProofLoop · Cost Of Inaction
17
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs. competitors.argue_timing
Open slide detailBeat · Evidence & ProofLoop · Cost Of Inaction
18
transition
Open slide detailBeat · Evidence & ProofLoop · Cost Of Inaction
19
The slide uses a two-column layout to contrast clinical results for Multiple Myeloma vs. AL Amyloidosis, supported by market data for existing therapies.show_traction
Open slide detailBeat · Evidence & ProofLoop · Cost Of Inaction
20
The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.compare_peers
Open slide detailBeat · Evidence & ProofLoop · Cost Of Inaction
21
The slide uses a red dashed box to highlight the core clinical data rows for comparison.compare_peers
Open slide detailBeat · Evidence & ProofLoop · Cost Of Inaction
22
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.show_traction
Open slide detailBeat · Impact & Next StepsLoop · Pareto Focus
23
The table uses a red dashed box to highlight the core clinical data rows.analyze_data
Open slide detailBeat · Impact & Next StepsLoop · Pareto Focus
24
The slide highlights specific safety data points for a competitor product to establish a benchmark.compare_peers
Open slide detailBeat · Impact & Next StepsLoop · Pareto Focus
25
The slide uses a structured table format to map clinical trial progress against specific disease indications.plan_implementation
Open slide detailBeat · Impact & Next StepsLoop · Pareto Focus
26
The diagram illustrates a dose escalation study design with three cohorts leading to the RP2D.plan_implementation
Open slide detailBeat · Impact & Next StepsLoop · Pareto Focus
27
The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.transition
Open slide detailBeat · Impact & Next StepsLoop · Pareto Focus
28
Includes scientific diagrams of molecular pathways and comparative efficacy charts.present_solution
Open slide detailBeat · Impact & Next StepsLoop · Pareto Focus
29
The slide uses three bar charts to compare IMX-110 performance against benchmarks in mouse models.show_traction
Open slide detailBeat · Impact & Next StepsLoop · Pareto Focus
30
Includes a process diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.show_traction
Open slide detailBeat · Impact & Next StepsLoop · Pareto Focus
31
Includes survival curves (Kaplan-Meier), tumor imaging, and tumor frequency metrics.show_traction
Open slide detailBeat · Impact & Next StepsLoop · Pareto Focus
32
transition
Open slide detailBeat · Impact & Next StepsLoop · Pareto Focus
33
Includes two side-by-side clinical data visualizations (line charts and bar charts) comparing patient outcomes.show_traction
Open slide detailBeat · Impact & Next StepsLoop · Pareto Focus
34
The slide uses a bubble chart to map clinical trial outcomes against patient treatment history and a table to detail specific drug performance metrics.frame_problem
Open slide detailBeat · Impact & Next StepsLoop · Pareto Focus
35
The chart is a conceptual visualization of 100% of patients achieving 4 months mPFS.show_traction
Open slide detailBeat · Impact & Next StepsLoop · Pareto Focus
36
Shows two parallel clinical tracks: monotherapy and combination with tislelizumab.plan_implementation
Open slide detailBeat · Impact & Next StepsLoop · Pareto Focus
37
transition
Open slide detailBeat · Solution & Approach
38
The slide uses a process-oriented layout to connect platform capabilities to specific product outputs.present_solution
Open slide detailBeat · Solution & Approach
39
The slide uses a process-like flow from the 3 pillars to the specific product applications.present_solution
Open slide detailBeat · Solution & Approach
40
Includes technical diagrams of the drug construct, comparative histology, and survival curves.present_solution
Open slide detailBeat · Solution & Approach
41
Includes two sets of charts: tumor volume line graphs and survival curves. References Abouzeid et al. (2013/2014).show_traction
Open slide detailBeat · Solution & Approach
42
Includes detailed scientific diagrams and references to clinical studies.present_solution
Open slide detailBeat · Solution & Approach
43
transition
Open slide detailBeat · Solution & Approach
44
The slide uses a grid-like layout to present headshots, names, titles, and institutional logos for advisory board members.other
Open slide detailBeat · Solution & Approach
45
other
Open slide detailBeat · Solution & Approach
46
The slide is divided into two rows: top row for ImmixBio board members, bottom row for Nexcella board members.other
Open slide detailBeat · Solution & Approach
47
appendix
Open slide detailBeat · Solution & Approach
48
The slide uses a bar chart to contrast two groups of drugs by their combined annual sales, effectively framing the market size for potential TSTx applications.size_opportunity
Open slide detailBeat · Solution & Approach
49
The slide compares efficacy of Humira, Stelara, and Entyvio against placebo in clinical trials.compare_peers
Open slide detailBeat · Solution & Approach